See Whole Prescribing Info OPDIVO® (nivolumab) is indicated with the treatment of Grownup patients with classical Hodgkin lymphoma (cHL) which has relapsed or progressed immediately after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or after 3 or even more strains of systemic therapy that features autologous HS… Read More